ÂÜÀòÂÒÂ×

JM

Jeffrey Enejosa, MD

Vice President Clinical Development at DICE Therapeutics

Jeffrey Enejosa, MD has extensive work experience in the field of clinical development and medicine. Jeffrey is currently serving as the Vice President of Clinical Development at DICE Therapeutics since June 2022. Prior to this, they held the same position at EQRx from October 2020 to June 2022.

Before joining DICE Therapeutics and EQRx, Dr. Enejosa worked at AbbVie from 2013 to 2020, holding various roles including Group Medical Director, Senior Medical Director, and Medical Director in Clinical Development. Jeffrey was responsible for overseeing and leading clinical research for the company.

Dr. Enejosa also has experience working as a Senior Director of Clinical Research at Tobira Therapeutics (2012-2013) and as the Director of Clinical Development and Head of Drug Safety and Pharmacovigilance at Dynavax Technologies (2011-2012).

In addition, they have practiced as an Internal Medicine Physician at Desert AIDS Project (2009-2011), Callen-Lorde Community Health Center (2002-2003), and in their private practice in Fort Lauderdale, FL (1996-2000).

Dr. Enejosa started their career at Gilead Sciences as a Director of Clinical Research from 2003 to 2009 and worked as an Associate Director of Medical Affairs at Bristol-Myers Squibb from 2000 to 2002.

Overall, Dr. Enejosa brings a wealth of experience and expertise in clinical development and medicine to their current role as Vice President of Clinical Development at DICE Therapeutics.

Jeffrey Enejosa, MD attended the University of the Philippines where they earned their MD degree in Doctor of Medicine. Jeffrey also completed their undergraduate studies at the same institution, majoring in BS Basic Medical Sciences. Following their medical studies, they pursued a post-graduate residency in Internal Medicine at New York Medical College. The exact years of their education are not provided.

Links

Previous companies

Gilead Sciences logo
AbbVie logo
Bristol-Myers Squibb logo
Dynavax Technologies logo